William Blair initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating. The firm says Aardvark is advancing ARD-101, an oral therapy that targets bitter taste receptors in the gastrointestinal tract, and ARD-201 for treating Prader-Willi syndrome and obesity. The company’s lead candidate ARD-101 is under Phase III investigation in Prader-Willi, which is associated with considerable unmet need, and ARD-201 in obesity “provides additional upside potential,” the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market Potential
- Aardvark Therapeutics’ Promising Progress and Market Potential: Analyst Recommends Buy
- Aardvark Therapeutics Begins Phase 3 HERO Trial Dosing
- Aardvark Therapeutics doses first patient in HERO trial
- Closing Bell Movers: Marvell up 11%, reversing initial earnings selloff